Recent Perspectives on Impulse Control Disorder in Dopamine Agonist-Treated Patients in Endocrine Practice

Abstract

AbstractDopamine agonists (DAs) are the primary treatment for patients with hyperprolactinemia. However, there are potential risks of impulse control disorders (ICDs), particularly in those with predisposing factors. Early recognition of ICDs is essential, as reducing the dose or discontinuing the medication often resolves the issue. In some cases, alternative treatments like surgery may be necessary, especially for microprolactinoma or intrasellar macroprolactinoma. Future research should focus on identifying confounding risk factors for ICD development, confirming the presence of ICDs with the help of psychiatrists, documenting the severity of ICDs, and providing guidance on optimal management strategies upon detection of ICDs. We here briefly review the frequencies, risk factors and provide practical guidance on identification and management of ICDs in the context of managing pituitary disorders.